Changing back effects of darbepoetin alfa on anemia treatment in hemodialysis patients treating with epoetin beta pegol

Therapeutic Research

Volumn 33, Issue 7, 2012, Pages 1095-1100

  Yamashita, Mitsuru ^a  

^a Okehazama Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON METABOLISM;

EID: 84865330972     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Erslev AJ. Erthropoietin. N Engl J Med 1991;324:1339-44.
2. Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The cardio-renal anaemia syndrome : Does it exist? Nephrol Dial Transplant 2003;18:S7-S12.
3. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5.
4. Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C. E. R. A. once every 4 weeks in patients with chronic kidney disease not on dialysis. Hemodial Int 2010;14:233-9.
5. Canaud B, Mingardi G, Braun J, Aljama R Kerr PG, Locatelli F, et al. Intravenous C. E. R. A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa : results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-61.